NASDAQ$EYPT
EyePoint Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2020.
EyePoint Pharmaceuticals reported total net revenue of $15.7 million for the third quarter of 2020, compared to $2.5 million for the same period in 2019. Net product revenue was $5.8 million, with $3.5 million from YUTIQ and $2.3 million from DEXYCU. The company's net loss was $3.8 million, or $0.03 per share, compared to a net loss of $15.6 million, or $0.15 per share, for the prior year quarter. Cash and cash equivalents as of October 31, 2020, were $30.5 million.
- Total revenues reached $15.7 million, with net product revenues of $5.8 million.
- Customer demand for DEXYCU increased by over 120% sequentially, while YUTIQ saw an increase of over 5%.
- The company's EYP-1901 remains on track for Q4 IND filing.
- The CRG debt facility was amended, waiving and modifying net product revenue covenants for 2020 and 2021, respectively.
Headline financials
Revenue & EPS history
EyePoint Pharmaceuticals · Revenue · Quarterly
$15.7M
Revenue by segment
EyePoint Pharmaceuticals · $15.7M total across 2 segments · Q3 2020
- License and Royalties$9.94M—63.3%
- Product sales, net$5.76M—36.7%
Forward guidance
EyePoint Pharmaceuticals expects that its existing cash and cash equivalents, combined with projected cash inflows from product sales and other financing activities, can fund operations into 2021, assuming no significant increase in COVID-19-related closures.
Tailwinds
- Existing cash and cash equivalents can fund operations into 2021.
- Projected cash inflows from YUTIQ and DEXYCU product sales will contribute to funding.
- Other expected financing activities will support operations.
- The company is actively assessing additional cash conservation measures.
- The company is actively assessing additional cash generation measures.
Headwinds
- Funding is contingent on no significant increase in COVID-19-related closures.
- COVID-19-related closures could materially affect ophthalmology office visits.
- COVID-19-related closures could materially affect the number of cataract surgical procedures.
- The company continues to assess additional cash conservation measures to support its operations through the COVID-19 pandemic.
- The company continues to assess additional cash generation measures to support its operations through the COVID-19 pandemic.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
-0.4%
Avg return
Earnings day
-1.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
48%
28 / 58 earnings
Positive
+21.1%
Q3 2023
Best reaction
-37.2%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +1.9% | -11.9% | |
| Q4 2025 | -1.9% | -14.5% | -26.9% | |
| Q3 2025 | -11.0% | -8.4% | +43.2% | |
| Q1 2025 | -2.2% | -6.4% | +43.0% | |
| Q4 2024 | +8.2% | +16.6% | -24.2% | |
| Q3 2024 | -3.7% | -8.0% | -27.9% | |
| Q2 2024 | +1.6% | -7.3% | -11.6% | |
| Q1 2024 | +6.7% | +2.9% | -23.3% | |
| Q4 2023 | -5.2% | -11.4% | -21.2% | |
| Q3 2023 | +21.1% | +26.7% | +9.8% | |
| Q2 2023 | -1.3% | -2.6% | -17.2% | |
| Q1 2023 | +4.5% | -0.3% | -7.9% | |
| Q4 2022 | +2.8% | -0.9% | -7.3% | |
| Q3 2022 | -1.3% | -3.5% | -37.5% | |
| Q2 2022 | +13.3% | +14.2% | -0.2% | |
| Q1 2022 | -4.9% | -19.5% | -23.8% | |
| Q4 2021 | +16.6% | +34.3% | +23.9% | |
| Q3 2021 | +10.1% | +26.1% | +18.6% | |
| Q2 2021 | +6.5% | +8.3% | +28.7% | |
| Q1 2021 | -8.1% | -14.8% | -12.0% | |
| Q4 2020 | -18.6% | -12.4% | -6.8% | |
| Q3 2020 | -7.5% | +10.0% | +30.0% | |
| Q2 2020 | -8.2% | -6.8% | -32.9% | |
| Q1 2020 | -3.3% | -2.2% | -8.9% | |
| Q4 2019 | -11.1% | -27.1% | -47.2% | |
| Q3 2019 | -37.2% | -41.6% | -35.1% | |
| Q2 2019 | +11.9% | +3.2% | +20.6% | |
| Q4 2018 | -3.5% | +2.2% | +41.0% | |
| Q3 2018 | +6.7% | -15.9% | -4.6% | |
| Q2 2018 | -2.7% | -5.5% | +12.7% | |
| Q1 2018 | -2.4% | +9.5% | +0.8% | |
| Q4 2017 | +1.6% | -5.5% | -3.1% | |
| Q3 2017 | +16.6% | +17.8% | +33.1% | |
| Q2 2017 | +4.1% | +5.3% | +0.0% | |
| Q1 2017 | +1.0% | -2.0% | -11.2% | |
| Q4 2016 | +1.6% | -4.1% | -35.7% | |
| Q3 2016 | +0.7% | — | — | |
| Q2 2016 | -10.1% | — | — | |
| Q1 2016 | -2.3% | — | — | |
| Q4 2015 | -1.3% | — | — | |
| Q3 2015 | -12.3% | — | — | |
| Q2 2015 | +2.3% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | -1.5% | — | — | |
| Q3 2014 | +2.2% | — | — | |
| Q2 2014 | +4.6% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q3 2012 | +2.1% | — | — | |
| Q4 2010 | -0.6% | — | — | |
| Q4 2012 | +3.1% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | -6.9% | — | — | |
| Q3 2011 | -5.5% | — | — | |
| Q1 2011 | +1.6% | — | — | |
| Q3 2010 | -1.7% | — | — | |
| Q1 2010 | -4.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro